Compare PepsiCo, Inc. (PEP) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PepsiCo, Inc. vs Repligen Corporation Common Stock — how do they compare? PepsiCo, Inc. trades at $129.94 (market cap $173.48B), while Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B). The key difference: PepsiCo, Inc. is far larger — about 15.6× Repligen Corporation Common Stock's market cap, and PepsiCo, Inc. pays a 4.65% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold PepsiCo, Inc. for 108 Days and Repligen Corporation Common Stock for 0 Days on average.
| PEP | RGEN | |
|---|---|---|
Market Cap | $173.48B | $11.14B |
Volume | 11,774,872 | 1,259,263 |
Sector | Consumer Staples | Health |
52-Week High | $170.44 | $194.57 |
52-Week Low | $123.64 | $102.87 |
Typical Hold Time | 108 Days | 0 Days |
Enterprise Value | $214.19B | $11.02B |
Dividend Yield | 4.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PepsiCo (PEP) trades at $129.27, up 2.01% with strong earnings momentum as the company has beaten EPS estimates for four consecutive quarters. The stock shows bearish technical signals but maintains solid fundamentals with $93.93B revenue and 11.09% net margin. Recent news highlights price adjustments on snack products and sponsorship changes, while analysts maintain a cautious outlook with 67.4% hold ratings.
PEP offers stable dividend income and consistent profitability, though near-term headwinds include pricing sensitivity and competitive pressures. The consensus price target of $142.38 suggests 10% upside potential, but technical weakness and mixed sentiment warrant careful monitoring of North American performance in upcoming earnings.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
